Form 4 for RGNX REGENXBIO Inc.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0001562180-25-000190 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-06 | 2025-01-02 | RGNX | PAKOLA STEVE | Chief Medical Off | F - Tax | $7.73 | -13.9K | 151.7K | -8% | -$107.4K |
| D | 2025-01-06 | 2025-01-02 | RGNX | PAKOLA STEVE | Chief Medical Off | A - Grant | $0.00 | +64.3K | 216.0K | +42% | $0 |
| D | 2025-01-06 | 2025-01-02 | RGNX | PAKOLA STEVE | Chief Medical Off | A - Grant | $0.00 | +103.7K | 103.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | F | D | 13,891 | $7.73 | 151,687 | D | — | — | (F1) Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2025 based on the closing price of the issuer's common stock on December 31, 2024. |
| 2 | Common | Common Stock | 2025-01-02 | A | A | 64,293 | $0.00 | 215,980 | D | — | — | (F2) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2026, January 1, 2027, January 1, 2028 and January 1, 2029 while the recipient provides continuous service to the Issuer. |
| 3 | Derivative | Stock Options (Right to buy) | 2025-01-02 | A | A | 103,698 | $0.00 | 103,698 | D | $7.86 · — to 2035-01-02 | 103,698 Common Stock | (F3) 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer. |